NDAORALCAPSULE
Approved
Sep 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TERRAMYCIN (oxytetracycline hydrochloride) is a tetracycline-class antibiotic approved in 1964 as an oral capsule for bacterial infections. It works by inhibiting bacterial protein synthesis, making it effective against a broad spectrum of gram-positive and gram-negative organisms. The drug is now in the LOE-approaching stage of its lifecycle.
LOE Approaching
With competitive pressure at 30% and approaching loss of exclusivity, the brand team is likely focused on retention and transition strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TERRAMYCIN offers limited career growth given its LOE-approaching status and minimal linked job openings. Opportunities are primarily in defensive commercial strategies, cost management, and compliance rather than innovation or expansion.
Brand ManagerSales Representative
Worked on TERRAMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.